Premium
In vitro susceptibility of Aspergillus and Fusarium associated with equine keratitis to new antifungal drugs
Author(s) -
Roberts Darby,
Cotter Henry Van T.,
Cubeta Marc,
Gilger Brian C.
Publication year - 2020
Publication title -
veterinary ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.594
H-Index - 50
eISSN - 1463-5224
pISSN - 1463-5216
DOI - 10.1111/vop.12774
Subject(s) - voriconazole , aspergillus fumigatus , aspergillus flavus , fungal keratitis , fusarium , microbiology and biotechnology , aspergillus , antifungal , keratitis , antifungal drug , biology , echinocandin , aspergillosis , pharmacology , medicine , fluconazole , immunology , botany , genetics
Objective To determine minimum inhibitory concentrations (MICs) of four fungal species isolated from horses presented with equine fungal keratitis (EFK) in the southeastern United States to previously untested azole, echinocandin, and carboxamide antifungal drugs. Methods In vitro assays were performed to determine the susceptibility of Aspergillus flavus , A. fumigatus , Fusarium falciforme, and F. keratoplasticum to five antifungal drugs representing three modes of action. Results Luliconazole exhibited increased growth inhibition against both Aspergillus and Fusarium compared to commonly used, standard antifungal drugs. MIC values for luliconazole at 0.001‐0.002 µg/mL were at least 25‐fold lower than all other antifungal drugs tested, including voriconazole. Conclusions The increased antifungal activity of luliconazole observed in this study warrants further investigation for its potential as an antifungal drug for equine fungal keratitis.